Comorbidity of severe psychotic disorders with measures of substance use - Wikidata - wikimedia - TriplyDB

Comorbidity of severe psychotic disorders with measures of substance use

Comorbidity of severe psychotic disorders with measures of substance use

http://www.wikidata.org/entity/Q33767822

about

Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies Smoking cessation and reduction in people with chronic mental illness Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.Engagement in assertive community treatment as experienced by recovering clients with severe mental illness and concurrent substance use Cannabis and Psychosis: a Critical Overview of the Relationship.The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability.An association between the use of hypnotics and quit status in the treatment of nicotine dependence with varenicline in bipolar disorder.Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region.Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis.Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders Nicotine dependence and psychosis in Bipolar disorder and Schizoaffective disorder, Bipolar type.E-cigarette Use in Veterans Seeking Mental Health and/or Substance Use Services.Gender Differences in Psychosocial Factors Associated with HIV Viral Suppression Among African-American Injection Drug Users.Schizophrenia and substance use comorbidity: a genome-wide perspective.Dual diagnosis in older adults: a review.How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactatio Improving Psychiatrists' Attitudes Towards Individuals with Psychotic Disorders and Co-Occurring Substance Use Disorders.Association between history of psychosis and cardiovascular disease in bipolar disorder.A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults.Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.Understanding How People with Mental Health Difficulties Experience Substance Use.Lifetime Prevalence and Correlates of Schizophrenia-Spectrum, Affective, and Other Non-affective Psychotic Disorders in the Chinese Adult Population.Brexpiprazole: A Review in Schizophrenia.Reactivity to addictive drugs in the methylazoxymethanol (MAM) model of schizophrenia in male and female rats.Redaction of Substance Abuse Claims in Medicare Research Files Affects Spending Outcomes for Nearly One in Five Beneficiaries with Serious Mental Illness.Substance use associated with short sleep duration in patients with schizophrenia or schizoaffective disorder.Counting up the risks: How common are risk factors for morbidity and mortality in young people with psychosis?Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations.Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder.Genetic correlation between smoking behaviors and schizophrenia.Polygenic risk scores for schizophrenia and bipolar disorder associate with addiction.Symptoms of psychosis in schizophrenia, schizoaffective disorder, and bipolar disorder: A comparison of African Americans and Caucasians in the Genomic Psychiatry Cohort.Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study.Smoking Topography Characteristics of Very Low Nicotine Content Cigarettes, With and Without Nicotine Replacement, in Smokers With Schizophrenia and Controls.Exposure to Kynurenic Acid during Adolescence Increases Sign-Tracking and Impairs Long-Term Potentiation in Adulthood.Association Between Substance Use Disorder and Polygenic Liability to Schizophrenia.

P2860

Q24289439-C218FB2B-A464-4C79-A7FD-A9EDBA5E8890 Q26782639-3CE0561B-82EC-4E23-9A9D-CE17B1A3E52F Q27303941-5486C95D-8901-4D10-BACF-5FD46515FF65 Q34248044-F3475FB4-299C-4BA4-A135-4AFCE9A56F9B Q34484841-99BB8C63-2133-4B4A-A11B-C72B5AD24B0E Q34509604-077BE9A0-77FA-429A-AC8E-A003D5675E7C Q34531537-A585A3F6-5E08-4A91-8054-0003C7973895 Q35130719-990AF1A1-C504-4647-B855-B72AD47D972D Q35701489-EBD09DF8-7650-4E23-9726-B1B7AD578854 Q35984960-DA81FCA8-EC4C-46B8-9CDA-CA8995246A61 Q36711713-BF3A6ED7-13AB-4F4E-9AAD-2B9976D1D7C0 Q36927085-B641126F-940E-494F-BE63-EC1D62F3279F Q37108596-5208A146-4AE8-44B5-A6D8-8F1474552826 Q37157557-EDC54757-115A-4E86-A78A-10AEFC34CE69 Q37437781-74EE25A4-36B5-41C7-8DCA-1B4C6D9FAF2A Q37713279-1B2CFC76-2DBE-4B85-A883-D486F98EA0F7 Q38334192-C09D3397-F11C-4299-9FAB-C6AF9BD9B78C Q38371207-C10A6065-8E16-4240-98DA-AFB47893B83A Q38395937-CC4A5143-F98D-49EF-88D1-BFDB07A0AACD Q38482147-FDC3BFDA-C725-4E80-8966-04F227A543BF Q38524175-1CF34103-C0ED-47D3-87A0-C3A9DCB89367 Q38559876-4310FAAC-878A-4DED-AE15-EE951361B497 Q38624500-79C0D2CF-7519-492E-ADC0-CD684A87B5E4 Q38692993-2385A377-4D13-4D90-9D10-8E180F821F21 Q38740652-426201DC-BF8D-4BD7-8FCC-C2A6813DF56E Q38740775-C27A5277-0C1E-4E59-AE44-4966161BB8F8 Q38792566-C6970BDD-3229-42FC-8676-40EA55D99FAF Q38862631-C665CAA8-08F9-417C-989F-3E4F099A1BAB Q38907203-165D7424-B15A-4BD3-8477-C1EC3A8D1E2D Q38966671-2FCC23F4-6188-412F-8E9D-3C2B16F56249 Q39176640-28DCE326-09DC-4ABD-8753-CDB7E8B3EAD6 Q39333786-B5EB7268-5657-446D-8CF4-6D27774C44C4 Q39480548-CA821BCF-4F56-4665-81D4-E0E3978E256D Q40296328-B920844B-82C2-4984-8ACC-3077FC245E1E Q40321770-FF013506-E22C-4667-9481-D16F5DDEC499 Q41053808-8BA11B28-6C3D-4268-814A-B8578C37DA7E Q41495390-8661D741-24AC-4B09-B044-1FB596282C93 Q41971019-40B11BC4-A1E7-49DF-8789-0350173B08E7 Q43092673-B9C50C06-658A-4CFD-966B-514D5E2DE38A Q46144362-6B5C82C1-E1AF-4A33-B9BF-8DA42AC1836D

P2860

Comorbidity of severe psychotic disorders with measures of substance use

http://www.wikidata.org/entity/Q33767822

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Comorbidity of severe psychotic disorders with measures of substance use

@ast

Comorbidity of severe psychotic disorders with measures of substance use

@en

type

label

Comorbidity of severe psychotic disorders with measures of substance use

@ast

Comorbidity of severe psychotic disorders with measures of substance use

@en

prefLabel

Comorbidity of severe psychotic disorders with measures of substance use

@ast

Comorbidity of severe psychotic disorders with measures of substance use

@en

P1433

Q33767822-B639ED41-BE91-46CF-B01A-E1DD2D6C370A

P1476

Q33767822-53A4479B-FFF0-4B35-BEAC-00585D24078A

P2093

Q33767822-0FA3DCD8-EEB3-4384-A0E6-1165E6EE70BF

Q33767822-2ED03449-4AEE-4E63-84D5-96A5CD6CAD71

Q33767822-6D5EA544-D427-4F6C-8E8E-2CE1F0C95813

Q33767822-74471D46-87EF-421F-A7DF-1B2FE2093CB3

Q33767822-C48881FD-2F04-473D-9D19-4A1D64127231

Q33767822-CD2E8A01-8301-4099-8172-CD567A8DD3FA

P2860

Q33767822-1C69618B-D1C8-47B0-8329-D9A2A8653640

Q33767822-584BE45E-25E0-4E32-BE98-B79C33D98B65

Q33767822-58CBA3D8-DD78-4F18-841B-F1779E318BE1

Q33767822-6129D7CF-8FDE-4AB0-86ED-66F7B914C835

Q33767822-6AEC5D00-992D-4F97-ABC8-E921143DC4D1

Q33767822-6C02655D-27F2-4CD9-8BB2-EDA264815AB6

Q33767822-6CB431BB-9E4D-42C4-9911-CA5A9A1B3621

Q33767822-6D564006-5331-4057-A16F-C58AA4A0D521

Q33767822-73A3F31B-01A8-4571-9147-2FC4723D6746

Q33767822-77275EA9-9BCE-4AC4-A0AD-759028525B57

P304

Q33767822-1F244782-D5DC-4F67-A438-3A3F9E8FB29E

P31

Q33767822-3735FBA8-F50F-463A-A7EA-5E312FC372F6

P356

Q33767822-CC1EAF6A-5746-426A-B3CC-D02500A14A46

P407

Q33767822-2F720749-7034-43BE-A450-C0D21AC710BB

P433

Q33767822-D3543763-36B3-41CA-8378-9367F8129248

P478

Q33767822-B614C283-3FE1-4F97-9E60-D4C9B728E210

P50

Q33767822-0D111902-D0BF-4664-A5B9-5A87B8CD9B0A

Q33767822-6E3F31E4-F56B-4B37-B56A-CD33CE592150

Q33767822-7D6BE4C2-FA2A-4271-84FE-9FD5DAF541CA

P577

Q33767822-48FFA80D-87E2-439A-8C2A-1A7BE77C946A

P698

Q33767822-BAF78778-683B-494C-8E1B-5C15DDFBC373

P921

Q33767822-FAB64A46-2E04-474F-980A-1E9C1F7D348C

P932

Q33767822-CABD9277-92DC-49F8-ADCA-29E427DEADB0

P356

JAMAPSYCHIATRY.2013.3726

P1433

JAMA Psychiatry

P1476

Comorbidity of severe psychotic disorders with measures of substance use

@en

P2093

Carlos N Pato

http://www.w3.org/2001/XMLSchema#string

Genomic Psychiatry Cohort Consortium

http://www.w3.org/2001/XMLSchema#string

Helena Medeiros

http://www.w3.org/2001/XMLSchema#string

James A Knowles

http://www.w3.org/2001/XMLSchema#string

Janet L Sobell

http://www.w3.org/2001/XMLSchema#string

Michele T Pato

http://www.w3.org/2001/XMLSchema#string

P2860

Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

Does this patient have an alcohol problem?

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

Prevalence and treatment of mental disorders, 1990 to 2003

The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R)

Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Substance use disorder comorbidity with schizophrenia in families of Mexican and Central American ancestry.

A population-based examination of cigarette smoking and mental illness in Black Americans

P304

248-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAPSYCHIATRY.2013.3726

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Patricia A. Cavazos-Rehg

Laura J. Bierut

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24382686

http://www.w3.org/2001/XMLSchema#string

P921

P932

4060740

http://www.w3.org/2001/XMLSchema#string